Viral dynamics in transplant patients: implications for disease.

Viral infections cause substantial morbidity and mortality in transplant patients. Quantifying viral loads is widely appreciated as a direct means to diagnose and monitor the course of viral infections. Recent studies indicate that the kinetics of viral load changes rather than single viral load measurements better correlate with organ involvement. In this Review, we will summarise the current knowledge regarding the kinetics of viruses relevant to transplantation including cytomegalovirus, Epstein-Barr virus, the herpes viruses 6 and 7, hepatitis C virus, GB virus C, adenovirus, and the emerging human polyomavirus type BK. We discuss the implications of viral kinetics for organ pathology as well as for the evaluation of antiviral interventions in transplant patients.

[1]  Guy Boivin,et al.  Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. , 2002, The Journal of infectious diseases.

[2]  J. Preiksaitis.  New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  A. L. Lloyd,et al.  The dependence of viral parameter estimates on the assumed viral life cycle: limitations of studies of viral load data , 2001, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[4]  F. Baldanti,et al.  Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. , 2002, Blood.

[5]  B. Sugden,et al.  Origins of bidirectional replication of Epstein–Barr virus: Models for understanding mammalian origins of DNA synthesis , 2005, Journal of cellular biochemistry.

[6]  F. Watzinger,et al.  Real-Time Quantitative PCR Assays for Detection andMonitoring of Pathogenic Human Viruses in ImmunosuppressedPediatricPatients , 2004, Journal of Clinical Microbiology.

[7]  D. Thorley-Lawson,et al.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas. , 2004, The New England journal of medicine.

[8]  Thomas F. Smith,et al.  Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. , 2003, The Journal of infectious diseases.

[9]  E. Rosenberg,et al.  Immune control of HIV-1 after early treatment of acute infection , 2000, Nature.

[10]  T. Berg,et al.  Dynamics of GB Virus C viremia early after orthotopic liver transplantation indicates extrahepatic tissues as the predominant site of GB virus C replication , 1999, Hepatology.

[11]  J. Steiger,et al.  Polyomavirus BK. , 2003, The Lancet. Infectious diseases.

[12]  P. Easterbrook,et al.  Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Perelson.  Modelling viral and immune system dynamics , 2002, Nature Reviews Immunology.

[14]  E. Claas,et al.  Quantification of adenovirus DNA in plasma for management of infection in stem cell graft recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Alan S. Perelson,et al.  Kinetics of Acute Hepatitis B Virus Infection in Humans , 2000, The Journal of experimental medicine.

[16]  A. Burroughs,et al.  Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. , 2005, Journal of Infectious Diseases.

[17]  S. Leung,et al.  Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  P. Bioulac-Sage,et al.  Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus–reinfected liver , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[19]  R. Siliciano,et al.  Taking aim at HIV replication , 2000, Nature Medicine.

[20]  H. Balfour,et al.  Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. , 1983, Annals of surgery.

[21]  Alan S. Perelson,et al.  In a Subset of Subjects on Highly Active Antiretroviral Therapy, Human Immunodeficiency Virus Type 1 RNA in Plasma Decays from 50 to <5 Copies per Milliliter, with a Half-Life of 6 Months , 2003, Journal of Virology.

[22]  Douglas D. Richman,et al.  Viral Dynamics of Acute HIV-1 Infection , 1999, The Journal of experimental medicine.

[23]  Andrew K Burroughs,et al.  Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. , 2002, The Journal of infectious diseases.

[24]  Hans H Hirsch,et al.  Polyomavirus-associated nephropathy in renal transplantation: critical issues of screening and management. , 2006, Advances in experimental medicine and biology.

[25]  N. Andrews,et al.  Population‐based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40 , 2003, Journal of medical virology.

[26]  Hans H Hirsch,et al.  Rapid dynamics of polyomavirus type BK in renal transplant recipients. , 2006, The Journal of infectious diseases.

[27]  T. Klimkait,et al.  Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. , 2002, The New England journal of medicine.

[28]  I. Ernberg,et al.  Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. , 2000, Blood.

[29]  M. Oldstone.  Viruses can cause disease in the absence of morphological evidence of cell injury: implication for uncovering new diseases in the future. , 1989, The Journal of infectious diseases.

[30]  G. Botti,et al.  Treatment of EBV‐Related Post‐Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV‐Specific T Cells , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  X. Forns,et al.  Hepatitis C virus kinetics during and immediately after liver transplantation , 2002, Hepatology.

[32]  K. Shimotohno,et al.  Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. , 2005, Molecular cell.

[33]  C. Lawson.  Cytomegalovirus after Kidney Transplantation: A Case Review , 2005, Progress in transplantation.

[34]  R. Freeman,et al.  The dispersal of mucosal memory B cells: evidence from persistent EBV infection. , 2002, Immunity.

[35]  H. Hirsch.  BK virus: opportunity makes a pathogen. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  L. Rostaing,et al.  Natural History of Hepatitis C Virus‐Related Liver Fibrosis After Renal Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[37]  R. May,et al.  Infectious Diseases of Humans: Dynamics and Control , 1991, Annals of Internal Medicine.

[38]  S. Finkelstein,et al.  Human polyoma virus-associated interstitial nephritis in the allograft kidney. , 1999, Transplantation.

[39]  M. Salizzoni,et al.  Quantitation of cytomegalovirus DNA by the polymerase chain reaction as a predictor of disease in solid organ transplantation. , 2004, Journal of medical virology.

[40]  S. Finkelstein,et al.  Quantitation of viral DNA in renal allograft tissue from patients with BK virus nephropathy1 , 2002, Transplantation.

[41]  L. M. Smith,et al.  Isolates of cytomegalovirus (CMV) from the black rat Rattus rattus form a distinct group of rat CMV. , 2004, The Journal of general virology.

[42]  M. Imperiale,et al.  BKV and SV40 infection of human kidney tubular epithelial cells in vitro. , 2004, Virology.

[43]  K. Roemer,et al.  Evaluation of Use of Epstein-Barr Viral Load in Patients after Allogeneic Stem Cell Transplantation To Diagnose and Monitor Posttransplant Lymphoproliferative Disease , 2002, Journal of Clinical Microbiology.

[44]  H. Hirsch.  Polyomavirus BK Nephropathy: A (Re‐)emerging Complication in Renal Transplantation , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[45]  Jean-Michel Pawlotsky,et al.  Hepatitis C virus genetic variability: pathogenic and clinical implications. , 2003, Clinics in liver disease.

[46]  Lee Cheng Zhao,et al.  Renal Ischemia/Reperfusion Injury Activates the Enhancer Domain of the Human Cytomegalovirus Major Immediate Early Promoter , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[47]  P. Bucsky,et al.  Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction12 , 2002, Transplantation.

[48]  Alan S Perelson,et al.  Estimates of Intracellular Delay and Average Drug Efficacy from Viral Load Data of HIV-Infected Individuals under Antiretroviral Therapy , 2004, Antiviral therapy.

[49]  F. Gudat,et al.  Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. , 1999, Transplantation.

[50]  P. Freimuth.  A human cell line selected for resistance to adenovirus infection has reduced levels of the virus receptor , 1996, Journal of virology.

[51]  R. Orentas,et al.  Monitoring and modulation of Epstein–Barr virus loads in pediatric transplant patients , 2003, Pediatric transplantation.

[52]  P. Griffiths,et al.  Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  J. Papadimitriou,et al.  Histological Patterns of Polyomavirus Nephropathy: Correlation with Graft Outcome and Viral Load , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[54]  H. Agut,et al.  Human herpesvirus (HHV)-6 and HHV-7: two closely related viruses with different infection profiles in stem cell transplantation recipients. , 2003, The Journal of infectious diseases.

[55]  Harel Dahari,et al.  Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. , 2005, Gastroenterology.

[56]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[57]  John McHutchison,et al.  Kinetics of hepatitis C virus reinfection after liver transplantation , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[58]  Emilio Ramos,et al.  Polyomavirus-associated nephropathy in renal transplantation , 2006 .

[59]  T. Berg,et al.  Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions , 1996, Hepatology.

[60]  C. Flaitz,et al.  Molecular markers of clonality and identity in epstein–barr virus‐associated B‐cell lymphoproliferative disease , 2004, Journal of medical virology.

[61]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[62]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[63]  E. De Clercq,et al.  Antiviral agents active against human herpesviruses HHV‐6, HHV‐7 and HHV‐8 , 2001, Reviews in Medical Virology.

[64]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[65]  Beda Joos,et al.  Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells. , 2001 .

[66]  Alan S. Perelson,et al.  A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo , 2003, Journal of Virology.

[67]  C. Benson,et al.  Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection , 1995 .

[68]  Huldrych F. Günthard,et al.  Quantification of In Vivo Replicative Capacity of HIV‐1 in Different Compartments of Infected Cells , 2001, Journal of acquired immune deficiency syndromes.

[69]  Sebastian Bonhoeffer,et al.  Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis , 1999, The Lancet.

[70]  F. Pereyra,et al.  Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients , 2004, Current opinion in infectious diseases.

[71]  A S Perelson,et al.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.

[72]  M. Suthanthiran,et al.  Polyomavirus-Associated Nephropathy in Renal Transplantation: Interdisciplinary Analyses and Recommendations , 2005, Transplantation.

[73]  F. Watzinger,et al.  Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. , 2003, Blood.

[74]  A S Perelson,et al.  Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. , 2000, The Journal of infectious diseases.

[75]  H. Hirsch.  Virus infections post transplant: risk and immunity , 2005, Transplant infectious disease : an official journal of the Transplantation Society.

[76]  Vincent C. Emery,et al.  Viral Dynamics during Active Cytomegalovirus Infection and Pathology , 2000, Intervirology.

[77]  H. Bazin,et al.  Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease1 , 2002, Transplantation.

[78]  D. Ho,et al.  Toward HIV eradication or remission: the tasks ahead. , 1998, Science.

[79]  R. Alemany,et al.  Blood clearance rates of adenovirus type 5 in mice. , 2000, The Journal of general virology.

[80]  Y. Karino,et al.  Hepatitis C virus genotypes and hepatic fibrosis regulate 24‐h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C , 2003, Journal of gastroenterology and hepatology.

[81]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[82]  M A Nowak,et al.  Viral dynamics in hepatitis B virus infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[83]  D. Maloney,et al.  Kinetics of B, CD4 T, and CD8 T cells infused into humans: estimates of intravascular:extravascular ratios and total body counts. , 2002, Clinical immunology.

[84]  Sebastian Bonhoeffer,et al.  Glancing behind virus load variation in HIV-1 infection. , 2003, Trends in microbiology.

[85]  F. Gudat,et al.  Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease. , 1999, Journal of the American Society of Nephrology : JASN.

[86]  A. Humar,et al.  Clinical impact of ganciclovir‐resistant cytomegalovirus infections in solid organ transplant patients , 2005, Transplant infectious disease : an official journal of the Transplantation Society.

[87]  F. Kern,et al.  Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients , 1999, Transplant infectious disease : an official journal of the Transplantation Society.

[88]  S. Harthug,et al.  The effect of treatment with alpha-interferon on hepatitis G/GBV-C viraemia. The CONSTRUCT Group. , 1998, Scandinavian journal of gastroenterology.

[89]  T. Shiohara,et al.  Virus-induced immune dysregulation as a triggering factor for the development of drug rashes and autoimmune diseases: with emphasis on EB virus, human herpesvirus 6 and hepatitis C virus. , 2000, Journal of dermatological science.